Document Detail

Usage of granulocyte colony-stimulating factor every 2 days is clinically useful and cost-effective for febrile neutropenia during early courses of chemotherapy.
MedLine Citation:
PMID:  20924633     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: In order to analyze the clinical activity and cost-effectiveness of granulocyte colony-stimulating factors (G-CSF), the prophylactic usage of G-CSF in patients treated with a single chemotherapy regimen during early courses was prospectively evaluated.
METHODS: Thirty patients with newly diagnosed non-Hodgkin lymphoma (NHL) treated with the first course of an R-CHOP regimen were enrolled randomly. After treatment with the first course of chemotherapy, a daily dose of G-CSF (lenograstim, 100 μg) was administered to half (15 cases) of the patients, and a dose of G-CSF (100 μg) was administered every other day to the other half of the patients when leukocytopenia (<1.5 × 10(9)/L) and/or neutropenia (<0.5 × 10(9)/L) occurred. Changes in leukocyte and neutrophil counts, prophylaxis, febrile neutropenia (FN) events, and cost performance between the two groups were analyzed.
RESULTS: No significant difference between the two groups was observed in recoveries of leukocyte and neutrophil counts and evidence of FN. The only difference was the total cost of G-CSF.
CONCLUSION: We concluded that every-other-day use of G-CSF was as clinically effective for the prophylaxis of FN as the daily use of G-CSF, and economically speaking, the administration of G-CSF every other day should be more beneficial for patients with NHL during early courses of R-CHOP chemotherapy.
Yoshihiro Yakushijin; Hisaharu Shikata; Ikue Takaoka; Tamami Horikawa; Kazuhito Takeuchi; Jun Yamanouchi; Taichi Azuma; Hiroshi Narumi; Takaaki Hato; Masaki Yasukawa
Related Documents :
11718213 - Anticipated administration of gm-csf in the treatment of non small cell lung cancer.
8033053 - Failure of a single cycle of high dose cyclophosphamide followed by intensive myeloabla...
23894153 - Retinoic acid plus arsenic trioxide, the ultimate panacea for acute promyelocytic leuke...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial     Date:  2010-10-06
Journal Detail:
Title:  International journal of clinical oncology     Volume:  16     ISSN:  1437-7772     ISO Abbreviation:  Int. J. Clin. Oncol.     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-04-07     Completed Date:  2011-07-28     Revised Date:  2012-12-13    
Medline Journal Info:
Nlm Unique ID:  9616295     Medline TA:  Int J Clin Oncol     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  118-24     Citation Subset:  IM    
Cancer Center of Ehime University Hospital, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime 7910295, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibiotics, Antineoplastic / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / administration & dosage,  adverse effects*,  therapeutic use
Cost-Benefit Analysis
Cyclophosphamide / administration & dosage,  adverse effects
Doxorubicin / administration & dosage,  adverse effects
Drug Administration Schedule
Fever / blood,  drug therapy*
Granulocyte Colony-Stimulating Factor / administration & dosage*,  economics
Leukocytes / drug effects
Lymphoma, Large B-Cell, Diffuse / blood,  drug therapy,  economics
Middle Aged
Neutropenia / blood,  drug therapy*,  economics
Neutrophils / drug effects
Prednisone / administration & dosage,  adverse effects
Recombinant Proteins / administration & dosage,  economics
Vincristine / administration & dosage,  adverse effects
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 0/Recombinant Proteins; 135968-09-1/lenograstim; 143011-72-7/Granulocyte Colony-Stimulating Factor; 23214-92-8/Doxorubicin; 50-18-0/Cyclophosphamide; 53-03-2/Prednisone; 57-22-7/Vincristine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Myotonic dystrophies as a brain disorder.
Next Document:  Tumor-infiltrating lymphocytes and hepatocellular carcinoma: molecular biology.